ZJ Bio-Tech: product approvals build pipeline, but losses widen
New product approvals expand addressable market ZJ Bio-Tech won three regulatory clearances: Vietnam certification for two products (July 20), a China Class III HPV genotyping kit (July 31), and a Class III monkeypox detection kit (Aug 19). These open new markets and enrich the product lineup, supporting future revenue growth.
These approvals are the main positive catalysts that could drive future sales and investor optimism.
Interim loss widens sharply on falling revenue First-half 2026 revenue fell 10.55% to 53.39 million yuan, while net loss widened to 40.59 million yuan from 9.85 million yuan a year earlier. Operating cash flow also dropped 55%. The weak financials weigh on the stock and raise doubts about near-term profitability.
The widening loss is the key fundamental negative that pressures the share price.
Company continues share buybacks ZJ Bio-Tech repurchased 5.51 million shares for 105 million yuan by Sept 30, up from 4.37 million shares in early August. Buybacks reduce shares outstanding and signal management confidence, offering some support to the stock price.
Buybacks are a capital action that can cushion the stock and show insider confidence.